In 2000, WuXi AppTec Group was founded in a 650-square-meter laboratory in Shanghai Waigaoqiao Free Trade Zone. For over a decade, developing from a laboratory with only a few employees to a company with over 20,000 employees and 32 branches around the world, and delisting from New York Stock Exchange (NYSE) in 2015 and listing in both A-share and H-share markets in 2018, WuXi AppTec Group has grown into an open-access capability and technology platform company, ranking No.1 in Asia Pacific and No.8 in the world.
As an innovation-driven and customer-focused company, WuXi AppTec Group provides a cost-effective and efficient service platform to help worldwide customers shorten the research and development (R&D) time and lower the R&D cost of drugs and medical devices. It is capable of providing customers with a broad and integrated portfolio of laboratory R&D and production services throughout the entire process from research, development, testing, production and clinical trials to the final sales and marketing phase. WuXi AppTec Group conducts research in a wide range of fields, including drug molecular design, chemical synthesis, analytical services, bio-analysis, technology R&D, API production, drug metabolism and pharmacokinetics, biological R&D, pharmacology, preparations, toxicology, genome, biologic preparation production, and the production, sale, clinical R&D and registration of antibodies and biological diagnostic reagents.
WuXi AppTec’s brand new service concepts and outstanding R&D service capability have been widely recognized by the government and society. It has won the following honors and qualification certificates: the State-Accredited Enterprise Technology Center (2014), the National Innovation-oriented Enterprise (2011), the National Key Laboratory for Drug Lead Compound Research approved by the Ministry of Science and Technology of China (2008), the Key Liaison Service Outsourcing Company (2012), the Top 50 Most Dynamic Services Trade Enterprises (2013), the Top Ten Chinese Outsourcing Enterprises (2009-2018), High-tech Enterprise (2013), the Overseas High-level Talent Innovation and Entrepreneurship Base of Shanghai (2012), the Certificate of Advanced Technology-Based Service Enterprise (2014), and Shanghai Enterprise Technology Center (2005).
Over the past more than a decade’s development, WuXi AppTec Group has been providing R&D services for more and more new drugs. For example, Merck Sharp & Dohme Corp. (MSD), a large American pharmaceutical company, only took nine years to launch Zepatier, a drug for the treatment of hepatitis C, in the U.S. and China. WuXi AppTec Group provided full-process services for Zepatier, from molecular design to marketing. The three scientists of WuXi AppTec Group who participated in the R&D of Zepatier were honored as “Heroes of Chemistry” by the American Chemical Society. From 2014 to 2017, 116 out of the 154 new drugs approved by the U.S. Food and Drug Administration (FDA) were developed by partners of WuXi AppTec Group; in 2017, 16 out of 51 new drug applications to the China Food and Drug Administration (CFDA) were submitted by partners of WuXi AppTec Group. Currently, WuXi AppTec Group has over 3,000 customers, including the world’s top 10 pharmaceutical and biochemical companies, such as Pfizer, MSD, GSK, and Amgen. With its excellent R&D service capability, WuXi AppTec Group has been honored as “the world’s leading R&D institution” by Merck & Co. and Pfizer.
WuXi AppTec Group is enabling thousands of R&D projects of more than 3,000 innovative collaborators from more than 30 countries to bring the best innovative medical and healthcare products to patients, thus fulfilling its dream that “every drug can be made and every disease can be treated.”